Is CJC-1295 safe?
CJC-1295 has not been shown to be safe for long-term use. FDA identifies limited clinical data and serious adverse events associated with it, including increased heart rate and systemic vasodilatory reactions.1 Short studies in healthy adults cannot establish the risks of ongoing treatment or a compounded combination.2
- Long-term safety
- Unknown in humans.3
- Commonly reported effects
- Injection-site reactions; other effects are summarized below.3
- Heart concerns
- A fatal heart attack was reported during an unpublished trial. Causation is not established.3
- Evidence limits
- Short healthy-adult studies do not establish safety for every formulation or patient.2
In this guide
Reported side effects
FDA’s advisory review describes injection-site reactions, flushing, headache, nausea, abdominal pain, diarrhea, dizziness, low blood pressure and increased heart rate. It also notes transient leg muscle contractions and impaired coordination.3
FDA notes that the exact study substance and salt were unclear. These findings concern DAC-related products and do not provide dependable event rates for every commercial vial, dose or combination. A trial reporting no serious adverse reactions does not mean participants had no side effects.2
CJC-1295 and heart attacks
FDA’s 2024 presentation summarizes anecdotal reports of a fatal heart attack after an eleventh weekly dose in an HIV-lipodystrophy trial. The attending physician attributed it to previously silent coronary artery disease and plaque rupture. The trial stopped; its data were not published.3
What the human studies establish
Teichman and colleagues reported two randomized, ascending-dose studies lasting 28 and 49 days in healthy adults. Their abstract reported no serious adverse reactions and described tolerability at the doses studied.2 Ionescu and Frohman published a separate study of hormone secretion.4 These are two papers describing different studies, not a total of two human trials.
The participants, follow-up and study purposes matter. Hormone-response studies can show that growth hormone and IGF-1 change without proving long-term safety, improved health or an acceptable risk profile for someone with an existing illness.
FDA warnings and approval
FDA’s compounding notice also flags immune-response and peptide-characterization concerns. CJC-1295 appears in the withdrawn-nomination table; that is distinct from the page’s Category 2 table.1
CJC-1295 is not FDA approved. The review cited here reports no major-regulator approval for either variant.5 A prescription or a pharmacy’s willingness to compound it is not evidence of FDA approval.
DAC forms and ipamorelin combinations
A product called CJC-1295 may contain a DAC-related form or a different peptide sold as “no DAC.” The names should not be treated as interchangeable. Our guide to CJC-1295 product names explains what to confirm on a prescription.
The literature reviewed for this site did not establish the safety of CJC-1295 taken with ipamorelin.5 Findings for either ingredient alone cannot establish the safety of the pair. See ipamorelin side effects for its separate evidence and limitations.
For a different molecule’s background, CJC-1295 vs sermorelin compares their properties. That comparison is not a recommendation to substitute one for the other.
Questions for a clinician
- What diagnosis and evidence would justify this specific prescription?
- Which peptide, salt form and formulation would I receive?
- How do my medical history, medications and cardiovascular risks affect the decision?
- Which side effects require stopping treatment or seeking urgent assessment?
- Who dispenses the medication, monitors me and handles adverse reactions?
If you are also comparing companies, use our provider-selection checklist and provider reviews to check published pharmacy, supply and fee information. Commercial availability does not establish clinical suitability.
Sources
5 documents, in the order the figures above use them. The date on each is the one printed on the document.
- Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.Document date: content current as of 04/22/2026. Category 2 of the bulk substances nominated under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.Document date: 2006-03. PMID 16352683, doi:10.1210/jc.2005-1536.
- U.S. Food and Drug Administration. December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting.Document date: 2024-12-04. FDA media 183891, pages 66–70.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.Document date: 2006-12. PMID 17018654, doi:10.1210/jc.2006-1702.
- Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Document date: 2026-06-18. PMID 42395176, PMC13322892, doi:10.3389/fendo.2026.1822475.